Inogen Future Growth

Future criteria checks 0/6

Inogen is forecast to grow earnings and revenue by 29.2% and 4.1% per annum respectively. EPS is expected to grow by 34.7% per annum. Return on equity is forecast to be -28.5% in 3 years.

Key information

29.2%

Earnings growth rate

34.7%

EPS growth rate

Medical Equipment earnings growth	18.3%
Revenue growth rate	4.1%
Future return on equity	-28.5%
Analyst coverage	Low
Last updated	29 Feb 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:6IO - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	358	-45	-24	20	2
12/31/2025	338	-52	-27	10	4
12/31/2024	324	-58	N/A	3	4
12/31/2023	316	-102	-30	-3	N/A
9/30/2023	328	-133	-43	-16	N/A
6/30/2023	349	-96	-55	-27	N/A
3/31/2023	369	-90	-50	-26	N/A
12/31/2022	377	-84	-59	-38	N/A
9/30/2022	366	-50	-36	-16	N/A
6/30/2022	353	-28	-31	-9	N/A
3/31/2022	351	-20	-20	3	N/A
12/31/2021	358	-6	0	24	N/A
9/30/2021	356	11	9	33	N/A
6/30/2021	337	-2	20	43	N/A
3/31/2021	307	-5	19	39	N/A
12/31/2020	308	-6	19	37	N/A
9/30/2020	313	-2	16	30	N/A
6/30/2020	331	6	29	38	N/A
3/31/2020	360	14	36	43	N/A
12/31/2019	362	21	34	41	N/A
9/30/2019	370	32	37	44	N/A
6/30/2019	373	42	34	43	N/A
3/31/2019	369	46	35	46	N/A
12/31/2018	358	52	47	60	N/A
9/30/2018	335	41	44	61	N/A
6/30/2018	309	32	49	64	N/A
3/31/2018	276	26	48	60	N/A
12/31/2017	249	21	50	60	N/A
9/30/2017	237	27	N/A	53	N/A
6/30/2017	222	25	N/A	44	N/A
3/31/2017	212	24	N/A	39	N/A
12/31/2016	203	21	N/A	31	N/A
9/30/2016	192	19	N/A	38	N/A
6/30/2016	179	17	N/A	41	N/A
3/31/2016	168	13	N/A	37	N/A
12/31/2015	159	12	N/A	38	N/A
9/30/2015	148	9	N/A	30	N/A
6/30/2015	136	9	N/A	21	N/A
3/31/2015	123	7	N/A	23	N/A
12/31/2014	113	5	N/A	16	N/A
9/30/2014	103	6	N/A	13	N/A
6/30/2014	94	3	N/A	15	N/A
3/31/2014	83	1	N/A	9	N/A
12/31/2013	75	0	N/A	13	N/A
9/30/2013	70	-3	N/A	13	N/A
6/30/2013	63	-4	N/A	9	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 6IO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 6IO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 6IO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 6IO's revenue (4.1% per year) is forecast to grow slower than the German market (5.5% per year).

High Growth Revenue: 6IO's revenue (4.1% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 6IO is forecast to be unprofitable in 3 years.

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Inogen Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Inogen, Inc. Provides Earnings Guidance for the First Quarter 2024

Inogen, Inc. Reiterates Earnings Guidance for the Year 2023

Inogen, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022

Inogen, Inc. Provides Earnings Guidance for the Second Quarter of 2022

Inogen, Inc. Provides Preliminary Unaudited Revenue Guidance for the Three-Month and Twelve-Month Periods Ended December 31, 2021

Inogen, Inc. Unable to Provide Guidance for the Full Year 2021

Recent updates

New minor risk - Shareholder dilution

Inogen, Inc., Annual General Meeting, Jun 05, 2024

Inogen, Inc. to Report Q1, 2024 Results on May 07, 2024

Inogen, Inc. Provides Earnings Guidance for the First Quarter 2024

Full year 2023 earnings released: US$4.42 loss per share (vs US$3.67 loss in FY 2022)

Inogen, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Inogen, Inc. Announces CFO Changes, Effective March 4, 2024

Inogen, Inc. Appoints Grgoire Ramade to Serve as Chief Commercial Officer

Inogen, Inc. Announces Separation Agreement with Nabil Shabshab

Inogen, Inc. Announces Separation Agreement with Nabil Shabshab

Inogen Announces CEO Changes

Third quarter 2023 earnings released: US$1.97 loss per share (vs US$0.41 loss in 3Q 2022)

New minor risk - Market cap size

Inogen, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Inogen, Inc. Announces Executive Changes

Second quarter 2023 earnings released: US$0.42 loss per share (vs US$0.15 loss in 2Q 2022)

Inogen, Inc. Announces the Introduction of the Rove 6(Tm) Portable Oxygen Concentrators in the United States

Inogen, Inc. Announces Board Changes

Inogen, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Inogen, Inc. Reiterates Earnings Guidance for the Year 2023

First quarter 2023 earnings released: US$0.88 loss per share (vs US$0.63 loss in 1Q 2022)

Full year 2022 earnings released: US$3.67 loss per share (vs US$0.28 loss in FY 2021)

Inogen, Inc. Announces Bart Sanford to Step Down as Executive Vice President, Operations Effective on or Before March 1, 2023

Inogen, Inc. to Report Q4, 2022 Results on Feb 23, 2023

High number of new and inexperienced directors

Third quarter 2022 earnings released: US$0.41 loss per share (vs US$0.54 profit in 3Q 2021)

Inogen, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022

Inogen, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Second quarter 2022 earnings released: US$0.15 loss per share (vs US$0.23 profit in 2Q 2021)

High number of new and inexperienced directors

Inogen, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Inogen, Inc.(NasdaqGS:INGN) dropped from Russell 2000 Growth-Defensive Index

Inogen, Inc. Names Agnes Lee as Senior Vice President of Investor Relations and Strategic Planning, Effective May 23, 2022

Inogen, Inc. Provides Earnings Guidance for the Second Quarter of 2022

High number of new and inexperienced directors

Inogen, Inc., Annual General Meeting, Jun 08, 2022

Inogen, Inc. Announces Management Changes

Inogen, Inc. to Report Q1, 2022 Results on May 05, 2022

High number of new and inexperienced directors

Inogen, Inc. Executive Changes

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Loren McFarland Not to Stand for Re-Election as Director of Inogen, Inc

Inogen, Inc. Provides Preliminary Unaudited Revenue Guidance for the Three-Month and Twelve-Month Periods Ended December 31, 2021

Third quarter 2021 earnings released: EPS US$0.54 (vs US$0.077 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS US$0.23 (vs US$0.12 in 2Q 2020)

Inogen, Inc.(NasdaqGS:INGN) dropped from Russell 3000E Value Index

Inogen, Inc. Unable to Provide Guidance for the Full Year 2021

Inogen Announces Board Changes

Inogen, Inc. Unables to Provide Guidance for the Full Year 2021

Inogen, Inc Announces Management Changes

Independent Director has left the company

Inogen, Inc. to Report Q4, 2020 Results on Feb 24, 2021

New 90-day high: €42.00

Inogen, Inc. Announces Change of Chief Executive Officers

Inogen, Inc. Announces Board Changes

Inogen, Inc. Unable to Provide Guidance for the Full Year 2020 or 2021

Inogen, Inc. to Report Q3, 2020 Results on Nov 04, 2020

New 90-day low - €22.80

New 90-day low - €24.80

First half earnings released

Inogen, Inc. to Report Q2, 2020 Results on Aug 04, 2020

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies